Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745] [0.03%]
“紫杉醇-卡铂新辅助化疗联合手术治疗局部晚期头颈部鳞癌的Ⅱ期临床研究”一文中表3的更正（107745）
Min Hee Hong,Seoyoung Lee,Chang Gon Kim et al.
Min Hee Hong et al.
Published Erratum
Oral oncology. 2026 Jun 20:108052. DOI:10.1016/j.oraloncology.2026.108052 2026
Evaluation of a quasi-automatic treatment planning workflow for head-and-neck cancer in radiotherapy [0.03%]
头部和颈部癌症放射治疗准自动治疗计划的工作流程评估
Erkan Topkan,Ugur Selek
Erkan Topkan
Predictors and outcomes of pathologic retropharyngeal lymph nodes in HPV-related oropharyngeal cancer [0.03%]
与HPV有关的口咽癌中病理后咽淋巴结的预后因素及其结局效果
Iulia Tapescu,Robert M Brody,Austin C Cao et al.
Iulia Tapescu et al.
Objectives: To determine the incidence of pathologic retropharyngeal lymph node (RPLN) metastases, evaluate the accuracy of preoperative imaging, identify predictors for RPLN involvement, and assess the impact of patholog...
Corrigendum to "Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials" [Oral Oncol. 174 (2026) 107858] [0.03%]
“序贯quarterback试验：低风险HPV阳性咽癌诱导化疗引导的减量同步放化疗长期结果”的勘误[《口腔肿瘤学》2026年第174期107858号论文]
J T Lovett,M T Wotman,W H Westra et al.
J T Lovett et al.
Published Erratum
Oral oncology. 2026 Jun 17:108053. DOI:10.1016/j.oraloncology.2026.108053 2026
Development of the TORS severe outcome score: a preoperative risk stratification tool for postoperative morbidity in oropharyngeal cancer [0.03%]
TORS术后严重预后评分（POD）的建立：一种术前风险评估工具，用于评估咽癌患者的术后发病率
Ismail M Khaderi,Nazineen Kandahari,Abdullah W Saleh et al.
Ismail M Khaderi et al.
Background: Transoral robotic surgery (TORS) is increasingly adopted for the treatment of oropharyngeal squamous cell carcinoma (OPSCC), with minimizing treatment-related morbidity remaining a key priority. We developed t...
Long-term outcomes, prognostic factors, and patterns of failure of postoperative adjuvant iodine-125 seed brachytherapy for parotid carcinoma: a large single-institution cohort [0.03%]
术后辅助125碘粒子种植治疗腮腺癌的远期疗效、预后因素及失败模式：单中心大样本回顾性分析
Zhenyu Li,Shu Yi,Yiwei Zhong et al.
Zhenyu Li et al.
Background: Evidence supporting postoperative iodine-125 (125I) seed brachytherapy for parotid carcinoma remains limited. This study evaluated its long-term efficacy, safety, and prognostic factors in a large single-insti...
Ewing sarcoma of the Mandible: a systematic review and pooled survival analysis [0.03%]
下颌尤因肉瘤的系统评价和生存率分析
Luca Canali,Andrea Costantino,Nicolò Berdin et al.
Luca Canali et al.
Background: Ewing sarcoma (ES) of the mandible is an extremely rare malignancy, representing less than 2% of all ES cases. Due to its low incidence, most available evidence derives from isolated case reports or small case...
Structure-specific involvement in advanced cervical lymph node extranodal extension predicts prognosis in nasopharyngeal carcinoma: A multi-center study [0.03%]
咽淋巴结结构特异性侵犯与鼻咽癌预后的关系：多中心研究
Junyi Liu,Yanxin Fan,Changyong He et al.
Junyi Liu et al.
Objective: To further investigate the prognostic value of advanced cervical lymph node (CLN) extranodal extension (ENE) involving different structures and its potential synergistic effects with other nodal features in nas...
Postoperative radiotherapy delineation after mandibular bone flap reconstruction in oral cavity and oropharyngeal cancers [0.03%]
下颌骨瓣移植后口腔和口咽癌术后放射治疗靶区勾画原则专家共识
Juliette Thariat,Pierre-Yves Marcy,Renaud Preudhomme et al.
Juliette Thariat et al.
Background: Postoperative radiotherapy is a cornerstone of management for locally advanced oral cavity and oropharyngeal cancers. Increasing use of vascularised mandibular bone flaps and patient-specific fixation systems ...
Intravenous amivantamab after cetuximab failure in recurrent or metastatic head and neck squamous cell carcinoma: a single-centre retrospective real-world cohort study [0.03%]
西妥昔单抗治疗失败后的复发或转移性头颈部鳞癌患者使用静脉注射Amivantamab的回顾性真实世界队列研究
Liqiong Xue,Jiuli Zhou,Wenbo Tang et al.
Liqiong Xue et al.
Background: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who exhaust platinum, immune checkpoint inhibitors (ICIs), and cetuximab lack standard options. The OrigAMI-4 trial showe...